Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women

AIDS Research and Human Retroviruses

Volumn 26, Issue 11, 2010, Pages 1181-1190

  Nel, Annalene M ^a   Coplan, Paul ^b   Smythe, Shanique C ^a   McCord, Karen ^a   Mitchnick, Mark ^c   Kaptur, Paulina E ^a   Romano, Joseph ^a  

^a INTERNATIONAL PARTNERSHIP FOR MICROBICIDES   (United States)

^b PFIZER INC   (United States)

^c Particle Sciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; DAPIVIRINE; MICROBICIDE; NITRITE; PROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GEL; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LEUKOCYTE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOUTH AFRICA; URINALYSIS; URINARY TRACT INFECTION; UTERINE CERVIX MUCUS;

ADMINISTRATION, INTRAVAGINAL; ADULT; ANTI-INFECTIVE AGENTS; BODILY SECRETIONS; CERVIX UTERI; DOUBLE-BLIND METHOD; FEMALE; GELS; HUMANS; PLASMA; PYRIMIDINES; SOUTH AFRICA; VAGINA;

EID: 78649266105     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0227     Document Type: Article

References (25)

1. Report on the global HIV/AIDS epidemic 2008: executive summary. July 2008. UNAIDS/08.27E/JC1511E. ISBN 978 92 9 173717 8. http://www.unaids.org/en/ KnowledgeCentre/HIVData/GlobalReport/2008/2008-Global-report.asp.
2. Kilmarx PH, van de Wijgert JH, Chaikummao S, et al.: Safety and acceptability of the candidate microbicide Carraguard in Thai women: findings from a phase II clinical trial. J Acquir Immune Defic Syndr 2006;43:327-334.
3. Morrow K, Rosen R, Richter L, et al.: The acceptability of an investigational vaginal microbicide, PRO 2000 gel, among women in a phase I clinical trial. J Womens Health (Larchmt) 2003;12:655-666.
4. Nel AM, Coplan P, van de Wijgert JH, et al.: Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy HIV-negative women. AIDS 2009;23:1531-1538.
5. Trottier S, Omar RE, Desormeaux A, et al.: Safety, tolerance and acceptability of the Invisible Condom® and its vaginal applicator in healthy women and their male sexual partners. Contraception 2007;76:117-125.
6. Malonza IM, Mirembe F, Nakabiito C, et al.: Expanded phase 1 safety and acceptability study of 6% cellulose sulfate vaginal gel. AIDS 2005;19:2157-2163.
7. Bentley ME, Fullem AM, Tolley EE, et al.: Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am J Public Health 2004;94:1159-1164.
8. D'Cruz OJ and Uckun FM: Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des 2004;10:315-336.
9. Nuttall JP, Thake DC, Lewis MG, Ferkany JW, Romano JW, and Mitchnick MA: Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days. Antimicrob Agents Chemother 2008;52:909-914.
10. Jespers VA, Van Roey JM, Beets GI, and Buvé AM: Doseranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers. J Acquir Immune Defic Syndr 2007;44:154-158.
11. Woolfson AD, Malcolm RK, Morrow RJ, Toner CF, and McCullagh SD: Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm 2006;325:82-89.
12. Malcolm RK, Woolfson AD, Toner CF, Morrow RJ, and McCullagh SD: Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother 2005;56:954-956.
13. Romano J, Malcolm RK, Garg S, Rohan LC, and Kaptur PE: Microbicide delivery: formulation technologies and strategies. Curr Opin HIV AIDS 2008;3:558-566.
14. Van Herrewege Y, Michiels J, Van Roey J, et al.: In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother 2004;48:337-339.
15. Fletcher P, Harman S, Azijn H, et al.: Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2009;53:487-495.
16. Di Fabio S, Van Roey J, Giannini G, et al.: Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the nonnucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 2003;17:1597-1604.
17. The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004. http://www.ucdmc.ucdavis. edu/clinicaltrials/documents/DAIDS-AE-GradingTable-FinalDec2004.pdf.
18. Nel A, Smythe SC, Habibi S, and Romano J: Pharmacokinetics of two dapivirine vaginal microbicide gels and their safety vs. hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr 2010 Jun. 22. [Epub ahead of print].
19. Van't Klooster G, van der Geest R, and Gillé D. Pharmacokinetics, tolerability and safety of multiple oral doses of TMC120 (R147681) in 32 healthy subjects. Tibotec Pharmaceuticals Ltd. Trial No. TIBO-0001-104, Report No. TMC120-C104-CRR, April 9, 2004.
20. Mayer KH, Maslankowski LA, Gai F, et al.: Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 2006;20:543-551.
21. Schwartz JL, Rountree R, Kashuba A, et al.: A multicompartment, single and multiple dose pharmacokinetic study of the candidate vaginal microbicide 1% tenofovir gel. 5th IAS Conference of HIV, Pathogenesis, Treatment and Prevention, Cape Town, South Africa, July 19-22, 2009, Abstract No. LBPEC03.
22. Kozal MJ: Drug-resistant human immunodeficiency virus. Clin Microbiol Infect 2009;Suppl 1:69-73.
23. Martinez J, Coplan P, and Wainberg MA: Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies? Antiviral Res 2006;71:343-350.
24. Mestecky J, Moldoveanu Z, Smith PD, Hel Z, and Alexander RC: Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection. J Reprod Immunol 2009;83:196-200.
25. Shacklett BL. Cell-mediated immunity to HIV in the female reproductive tract. J Reprod Immunol 2009;83:190-195.